# Alzheimers Disease Patient Registry

> **NIH NIH U01** · MAYO CLINIC ROCHESTER · 2022 · $3,907,919

## Abstract

ABSTRACT
The Mayo Clinic Study of Aging (MCSA) has been functioning as a population-based study of cognition
and aging since 2004. Over that timeframe, we have evaluated longitudinal cognitive trajectories of
individuals who are cognitively normal, have mild cognitive impairment (MCI) and dementia. We have
evaluated epidemiologic features of MCI and in recent years have evaluated many of the biomarkers of
aging and Alzheimer's disease (AD) including MRI, FDG PET, amyloid PET and tau PET. In the
current application, we will evaluate the recently published National Institute on Aging-Alzheimer's
Association AD Research Framework using our population-based cohort. In Aim 1, we will predict and
assess the role of risk factors of cognitive decline using the Framework's syndromic clinical
classification of cognitively unimpaired, MCI and dementia participants. In Aim 2, we will predict
cognitive decline in the Framework according to the newly proposed numeric staging scheme for
randomized controlled trials among amyloid positive persons. In addition, since we are evaluating a
representative sample of the entire community, we will also evaluate the numerical staging scheme in
amyloid negative persons as well as in the entire population. Since it is recognized that
cerebrovascular disease plays an important role in aging, in Aim 3 we will evaluate the impact of
cerebrovascular disease in aging and cognition as well as its interactions with AD pathology. We will
also develop novel MRI cerebrovascular disease measures using advanced methods. Biomarker
measures of AD are often expensive and/or invasive, and, as such, are not practical from a public
health perspective, and, therefore, in Aim 4, we will determine and compare the utility of plasma
amyloid-beta, p-tau181, total tau and neurofilament light (NfL) as noninvasive biomarkers of cognitive
decline and assess interactions with imaging biomarkers of amyloid, tau, neurodegeneration and
vascular disease. Finally, since sharing the rich resources of the MCSA are important, in Aim 5, we
outline our proposed mechanisms for data sharing that include review of proposals, standardized data
sharing agreements and logistics for sharing the data. We are hopeful that the continuation of the
MCSA will provide valuable information for the field of aging and AD.

## Key facts

- **NIH application ID:** 10435489
- **Project number:** 5U01AG006786-37
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Jonathan Graff-Radford
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $3,907,919
- **Award type:** 5
- **Project period:** 1986-09-30 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10435489

## Citation

> US National Institutes of Health, RePORTER application 10435489, Alzheimers Disease Patient Registry (5U01AG006786-37). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10435489. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*